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Abstract
The activity of cytochrome P450 enzymes depends on the enzyme NADPH P450
oxidoreductase (POR). The aim of this study was to investigate the activity of the
equine CYP3A94 using a system that allows to regulate the POR protein levels in
mammalian cells. CYP3A94 and the equine POR were heterologously expressed in
V79 cells. In the system used, the POR protein regulation is based on a
destabilizing domain (DD) that transfers its instability to a fused protein. The
resulting fusion protein is therefore degraded by the ubiquitin-proteasome system
(UPS). Addition of ‘‘Shield-1’’ prevents the DD fusion protein from degradation. The
change of POR levels at different Shield-1 concentrations was demonstrated by
cytochrome c reduction, Western immunoblot analysis, and immunocytochemistry.
The alteration of CYP3A94 activity was investigated using a substrate (BFC) known
to detect CYP3A4 activity. Equine CYP3A94 was demonstrated to be metabolically
active and its activity could be significantly elevated by co-expression of POR.
Cytochrome c reduction was significantly increased in V79-CYP3A94/DD-POR
cells compared to V79-CYP3A94 cells. Surprisingly, incubation with different
Shield-1 concentrations resulted in a decrease in POR protein shown by Western
immunoblot analysis. Cytochrome c reduction did not change significantly, but the
CYP3A94 activity decreased more than 4-fold after incubation with 500 nM and
1 mM Shield-1 for 24 hours. No differences were obtained when V79-CYP3A94
POR cells with and without Shield-1 were compared. The basal activity levels of
V79-CYP3A94/DD-POR cells were unexpectedly high, indicating that DD/POR is
not degraded without Shield-1. Shield-1 decreased POR protein levels and
CYP3A94 activity suggesting that Shield-1 might impair POR activity by an
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unknown mechanism. Although regulation of POR with the pPTuner system could
not be obtained, the cell line V79-CYP3A94/DD-POR system can be used for
further experiments to characterize the equine CYP3A94 since the CYP activity
was significantly enhanced with co-expressed POR.
Introduction
Cytochrome P450 enzymes (CYPs) are accountable for the metabolism of a
variety of endogenous and exogenous substances. These enzymes are involved in
physiological processes such as the biosynthesis and degradation of steroids,
cholesterol, and other endogenous compounds, but they are also responsible for
the biotransformation of drugs and toxins [1, 2].
To date, 18 CYP families have been discovered in humans; the CYP families 1–3
are referred to as the most important enzymes for the biotransformation of drugs
[3]. Since they play a key role in many drug-drug interactions, research on these
CYPs is of prime importance. To predict interactions between two and more
therapeutics detailed knowledge about single CYPs is essential.
Whereas human and laboratory animal CYPs have been investigated thoroughly
[2, 4, 5], little is known about CYPs in companion animals including the horse.
Although complex medical care and multidrug treatment became more important
in equines, knowledge about equine CYPs requires further in depth investigation.
The human CYP3A subfamily is known to be responsible for the metabolism of
more than one-third of all therapeutics. Genes coding for the human CYP3A subfamily
include CYP3A4, CYP3A5, CYP3A7, and CYP3A43 with CYP3A4 and CYP3A5 being
the most important ones for drug metabolism [6]. In equines, the entire CYP3A
subfamily gene cluster has been recently annotated by our group and consists of seven
genes: CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96, CYP3A97 and CYP3A129
[7]. To date, only a few studies are available on equine CYP genes, their expression
levels in equine tissues [7–10], and their functional characterization [11–14]. CYP3A94
is one of the highly expressed equine CYPs in the liver but no functional studies are
available in the literature [9]. To properly characterize equine single CYPs,
heterologous expression of CYPs using an in vitro system is necessary.
The enzyme NADPH P450 oxidoreductase (POR) is crucial for the function of
CYPs [15, 16]. This enzyme is a membrane-bound flavoprotein in the
endoplasmic reticulum (ER) that consists of two domains; one domain contains
the nicotine adenine dinucleotide phosphate (NADPH) binding site and flavin
adenine dinucleotide (FAD), and the other domain includes flavin mononu-
cleotide (FMN), which interacts with CYPs and other enzymes such as heme
oxygenase and enzymes for sterol biosynthesis. POR has been demonstrated to
enhance the catalytic activity of CYPs by supplying electrons to the CYP catalytic
cycle [17]. In addition, it has already been shown that the POR:CYP ratio is
important for optimal CYP activity. Depending on the CYP and the substrate,
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different POR:CYP ratios are necessary to achieve maximal CYP activity [14]. In
order to study different POR:CYP ratios for each CYP, an in vitro system allowing
regulation of POR levels would be an advantage.
Hamster lung fibroblasts (V79 cells) have frequently been used for
characterization of single CYPs because of the absence of endogenous CYP activity
and other advantages such as fast growth and a stable karyotype [12, 18, 19]. Since
it is known that the level of POR in V79 cells is relatively low [20], it is likely that a
low endogenous levels of POR is a limiting factor for the activity of CYPs
heterologously expressed in V79 cells. Schneider et al. and Schmalix et al. reported
that the activity of heterologously expressed CYPs in V79 cells was increased after
POR co-expression [20, 21].
Overall, this cell line is suitable for regulation of POR due to its low background
activity of endogenous POR.
The system used in this work facilitates the regulation of specific protein levels
in mammalian cells. The protein regulation is based on a protein destabilizing
domain (DD) that transfers its instability to a fused protein of interest and the
resulting fusion protein is therefore degraded by the ubiquitin-proteasome system
(UPS) [22–24]. Addition of a small and specific molecule (Shield-1) prevents the
DD fusion protein from degradation and leads to accumulation of the protein in
the cell [24]. Several reasons led to the decision to use the pPTuner system: its
reversibility, specificity and the fast and easy regulation on protein level.
The goals of this study were to stably express the equine CYP3A94 in V79 cells,
establish an in vitro system enabling the rapid and sensitive regulation of POR-
concentrations in the cell, and to investigate the activity of CYP3A94 at different
POR concentrations.
Materials and Methods
RNA extraction, cDNA synthesis and amplification of equine POR
Liver samples were taken at the abattoir (Horisberger, Burgdorf, Switzerland)
from an 18 year old warmblood mare within 30 minutes after slaughter. Total
mRNA was extracted from small liver samples of about 25 mg using TRIzol
Reagent (Invitrogen, Carlsbad, CA, USA) and RNeasy Kit (Qiagen, Hilden,
Germany). Reverse transcription of 1 mg total RNA to cDNA was performed with
QuantiTect Reverse Transcription (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s manual.
Primers located in the ATG (59-ATGGGGGACTCCAACATGG-39) and TAG
(59-CTAGCTCCACACGTCCAGC-39) region were used to amplify the complete
coding sequence (CDS) of the equine POR. The primers were designed manually
or using Primer3 software (http://www.bioinformatics.nl/cgi-bin/primer3plus/
primer3plus.cgi) and compared to the equine RefSeq mRNA data bank using
NCBI BLAST search (http://blast.ncbi.nlm.nih.gov) to avoid unspecific binding.
The primers were synthesized by Microsynth (Balgach, Switzerland). PCR
reactions were performed with TopTaq DNA Polymerase (Qiagen, Hilden,
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Germany) and repeated on the cDNA of the liver of three other horses (two
female, one male, 3–24 years, 2 warmbloods and one Freiberger; tissue samples
were obtained from the abattoir Horisberger (Burgdorf, Switzerland) [25].
Subsequently, the PCR products were sequenced in order to find possible
polymorphisms using an automated ABI 3730 capillary sequencer (Applied
Biosystems, Carslbad, CA, USA). Internal sequencing primers were used in
addition to the PCR primers used for amplification of the gene. The resulting
DNA sequence was compared to the published sequence of equine POR
(NM_001122655) using Sequencher 4.9 (GeneCodes, Ann Arbor, MI, USA).
Construction of expression vectors and cloning
The equine CYP3A94 sequence corresponds to the one published by Schmitz et al.
and is deposited in the EMBL data bank under the reference number
NM_001190939 [7]. The cDNA encoding the CYP3A94 was amplified using
Expand High Fidelity Plus PCR System (Roche Basel, Switzerland). Primers were
designed manually including the sequence of an HA-tag at the 39- end that can be
used for detection since specific antibodies detecting this CYP isoform are not
available. Subsequent sequencing was performed to check the sequence of the
inserts. PCR products were next digested with RsrII and subsequently cloned into
the RsrII-cleaved lentiviral vector pRRL 2xRsrII TD as described elsewhere
[26, 27] (kindly provided by Patrick Salomon, University of Geneva, Switzerland).
The pPTuner system from Clontech (Mountain View, CA, USA) was used to
regulate the expression levels of POR. The equine POR coding sequence was
cloned into the multiple cloning site (MCS) directly behind a destabilizing
domain (DD) to construct a fusion protein. This protein construct named DD/
POR is expected to be unstable and degraded by the ubiquitin-proteasome system.
Addition of the small, synthetic and specific ligand Shield-1 to the cell culture
medium results in binding of Shield-1 to the DD domain of the fusion protein.
Consequently, the DD protein is folded correctly, thus preventing its degradation.
Hence the DD/POR protein accumulates in the cell if Shield-1 is added [24].
To construct the vector with DD/POR as a fusion protein, the complete coding
sequence of the equine POR was cloned into the MCS of the vector pPTuner
IRES2 (Clontech, Mountain View, CA, USA) using the Infusion Dry Down
Cloning Kit (Clontech, Mountain View, CA, USA) according to the manufac-
turer’s recommendations. Afterwards, the sequence DD/POR was cloned into the
lentivirus vector pRRL 2x RsrII TD as described above.
Production of two stable cell lines V79-CYP3A94 and V79-
CYP3A94/DD-POR
HEK T293 cells (CRL-11268, ATCC) were cultivated in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal calf serum, 4 mM L-glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin.
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V79 cells (a kind gift of J. Buters, TU Mu¨nchen, Germany; [28]) were cultivated
in DMEM supplemented with 10% fetal calf serum, 1 mM sodium pyruvate,
4 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (all reagents
were purchased from Gibco, Carlsbad, CA, USA).
For virus production HEK T293 cells were grown to 70% confluence in
150 mm dishes (TPP, Trasadingen, Switzerland) and were chemically transfected
with FuGene HD Transfection Reagent (Roche, Basel, Switzerland) at a 3:1 ratio
FuGene:DNA, with 5 mg of the pRRL vector containing the sequence of CYP3A94
or DD/POR, respectively, 3 mg of the packaging protein-expressing vector (pPax2)
and 2 mg of the envelope protein VSV-G-expressing vector (pMD2G). Virus stock
was collected at day 2 and day 3 after transfection. Authorisation for the use of
this cell line has been given by the Federal Office for the Environment, Federal
Coordination Centre for Biotechnology in Bern, Switzerland (#A141301).
To produce the stable cell line V79-CYP3A94, native V79 cells were grown to
30% confluence in 6-well-plates (TTP, Trasadingen, Switzerland) and transduced
three times with 2 ml of virus stock each, containing CYP3A94. Transduction
efficiency was monitored by immunocytochemistry with an antibody against the
HA tag (mouse anti-HA, 1:100, Covance, Princeton, NJ, USA) and a goat anti-
mouse as secondary antibody (Alexa Fluor 488, 1:500, Rockland, Gilbertsville, PA,
USA). To ensure a homogenous cell line, single cell-clones were selected based on
a stable and intense fluorescence signal and were further cultivated. DNA
sequencing was conducted to confirm that the cells contain the new gene.
For production of the stable cell line V79-CYP3A94/DD-POR, one defined
clone of the cell line V79-CYP3A94 was grown to 30% confluence in 6-well-plates
(TTP, Trasadingen, Switzerland) and transduced three times with one passage in
between with 2 ml of virus stock each containing DD/POR. Transduction
efficiency was monitored by immunocytochemistry with an antibody against the
DD protein (mouse anti-DD-antibody, 1:200, Clontech, Mountain View, CA,
USA) and a goat anti-mouse as secondary antibody (Alexa Fluor 488 mouse anti-
HA, 1:500, Rockland, Gilbertsville, PA, USA). Single cell-clones were selected for
this cell line as well, and DNA sequencing was performed to confirm the presence
of DD-POR.
Regulation of POR
To regulate POR in V79-CYP3A94/DD-POR cells, Shield-1 (Clontech, Mountain
View, CA, USA) was added to the cell culture medium for 6 or 24 hours at
100 nM, 500 nM or 1 mM, respectively. In addition, the cells were incubated with
the solvent ethanol using the respective concentrations and incubation times.
Cell viability and total cellular protein
Cell viability was tested after incubation with the different substances using
PrestoBlue (Invitrogen, Carlsbad, CA, USA), a resazurin based cell viability
reagent. Briefly, PrestoBlue was added 1:10 to the cell culture medium at the end
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of the incubation time and incubated for additional 30 minutes at 37 C˚. The
fluorescent signal was measured with a plate reader (HT Synergy, Biotek,
Winooski, VT, USA) using an excitation of 530/25 nm and emission detection of
590/35 nm.
Total cellular protein was measured using o-phthalaldehyde (OPA), a primary
amine-reactive fluorescent detection reagent from Thermo Scientific (Waltham,
MA, USA). OPA (50 ml) was added to 50 ml sample and fluorescence was
measured using a plate reader (HT Synergy, Biotek, Winooski, VT, USA) after
5 minutes incubation time using 360/40 nm for excitation and 460/40 nm for
emission.
POR activity
To measure POR activity, a cytochrome c reductase assay (Sigma-Aldrich, St.
Louis, MO, USA) was performed using a slightly modified protocol compared to
the manufacturer’s instructions. Briefly, cells were grown in 24-well-plates to 80%
confluence at time of incubation with the substances. Total cellular protein was
harvested as described elsewhere [20]. 40 mg of total cellular protein was used for
each reaction performed in 96-well plates (Greiner, Kremsmu¨nster, Austria).
Reduced cytochrome c was detected by measuring the absorption at 550 nm for
5 minutes with a plate reader (HT Synergy, Biotek, Winooski, VT, USA). To
adjust the values to a 1 cm cuvette, path length was corrected using the plate
readers program Gene 5 (Version 2.1., Biotek, Winooski, VT, USA). The
cytochrome c reduction was calculated using a molar extinction coefficient for
reduced cytochrome c of 21 mM21 cm21.
CYP3A94 activity
To determine the activity of equine CYP3A94, a fluorescence-based assay with 7-
benzyloxy-4-trifluoromethylcoumarin (BFC), purchased from BD Gentest
(Franklin Lakes, NJ, USA), was performed as described previously [29]. Cells were
seeded in 24-well plates to 80% confluence at the time of incubation with BFC and
the additional substances, e.g. Shield-1. 100 mM BFC was directly added to the cell
culture medium and incubated for 24 hours, unless indicated otherwise.
Afterwards, the supernatant was diluted 1:2 with a quenching solution (0.25 M
Tris in 60% (v/v) acetonitrile). The metabolism from BFC to the fluorescent
metabolite 7-hydroxy-4-trifluoromethylcoumarin (HFC) was measured with a
plate reader (HT Synergy, Biotek, Winooski, VT, USA) using excitation at 400/
30 nm and emission at 530/25 nm.
Substances interacting with the UPS and ERAD
Substances interacting with the UPS and ER-associated protein degradation
(ERAD) were tested in V79-CYP3A94/DD-POR cells to investigate the
degradation of the DD/POR protein and its behavior after Shield-1 incubation.
Tunicamycin, an ER stress inducer activating the ER UPS (1 mM), brefeldin A, an
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inhibitor of the ER- to-Golgi transport (3.57 mM) and MG132, a chemical
inhibitor of proteasomes (1 mM, purchased from Sigma-Aldrich, St. Louis, MO,
USA) were incubated for 6 hours. Simultaneously, the cells were incubated with
BFC and with or without Shield-1 (1 mM) for 6 hours or with ethanol as vehicle
control. At the end of the incubation time, CYP3A94 activity and cell viability
were measured as described above. Concentrations of tunicamycin, brefeldin A,
and MG132 are based on preliminary tests in our laboratory and literature data to
minimize effects on cell viability and guarantee an effective concentration of the
compounds used [30–32].
Western immunoblot analysis
V79-CYP3A94/DD-POR cells were cultured in 24-well plates incubated with
Shield-1 for 24 hours at concentrations of 100 nM, 500 nM, and 1 mM,
respectively. V79-CYP3A94 cells were used as negative control. Total cellular
protein was extracted as described elsewhere [20]. Briefly, the cells were scraped
from the wells and centrifuged at 1500 g. The resulting cell pellet was shock-
frozen in liquid nitrogen and stored at 280 C˚. Protein from a 7.5% SDS-PAGE
gel was transferred to a PVDF membrane (Millipore, Billerica, MA, USA).
Membranes were blocked with 1% casein in PBS (Biorad, Hercules, CA, USA) for
1 hour at RT and incubated over night at 4 C˚ with three antibodies: mouse anti-
DD antibody (1:1000, Clontech, Mountain View, CA, USA), mouse anti-HA
antibody to mark CYP3A94 (1:1000, Covance, Princeton, NJ, USA), and mouse
anti-actin antibody (1:16’000, DSHB, University of Iowa) for normalization to a
housekeeping gene. The membranes were washed with TBST buffer and exposed
to the secondary antibody IRDye 800 goat anti-mouse (Rockland, Gilbertsville,
PA, USA) at a dilution of 1:10’000 for 1 hour at room temperature. For signal
detection and densitometric analysis Odyssey CLx infrared imaging system (LI-
COR, Lincoln, NE, USA) and the Odyssey analysis software version 2.1 (LI-COR,
Lincoln, NE, USA) were used.
Immunocytochemistry
V79-CYP3A94/DD-POR and V79-CYP3A94 cells (control) were cultured on
12 mm coverslips (Menzel GmbH, Braunschweig, Germany), in 24 well plates
(TPP, Trasadingen, Switzerland) as described above. Shield-1 was added to obtain
a final concentration of 1 mM and incubated for 24 hours. The cells were fixed
with 4% paraformaldehyde for 20 minutes and permeabilized with 2% Triton-X-
100 for 20 minutes at room temperature. Subsequently, the cells were incubated
simultaneously with primary antibodies (mouse anti-DD-antibody 1:500
(Clontech, Mountain View, CA, USA and either with an endoplasmic reticulum
marker, rabbit anti-calnexin-antibody 1:500 (Novus Biologicals, Cambridge, UK)
or a Golgi complex marker, rabbit anti-giantin-antibody 1:1000 (Abcam,
Cambridge, UK)) for 2 hours at room temperature. To detect the anti-DD-
antibody a goat anti-mouse antibody with Alexa Fluor 555 as a fluorochrome was
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used. A goat anti-rabbit antibody with Alexa Fluor 488 as a fluorochrome was
used to detect the anti-calnexin-antibody and anti-giantin-antibody (all secondary
antibodies: 1: 500, Rockland, Gilbertsville, PA, USA). All secondary antibodies
were incubated together with Hoechst 33342 (1:10000, Invitrogen, Carlsbad, CA,
USA) for 1 hour at room temperature. All washing steps were performed with
PBS. Finally, coverslips were mounted onto microscope slides with fluorescence
mounting medium (Dako, Glostrup, Denmark) and dried for 1 hour at room
temperature. Subsequently, the staining was observed, and images were captured
with a fluorescence microscope (Zeiss Axio Imager Z.1 equipped with an
AxioCam MRm digital camera, Carl-Zeiss AG, Feldbach, Switzerland). All
experimental and corresponding control images were obtained with identical
camera settings. Computer software (ImageJ, version 1.4.3, National Institutes of
Health, Bethesda, Md. Available at: rsbweb.nih.gov/ij/index.html.) was used to
adjust the contrast equally for experimental and control images.
Statistical analysis
Data from experiments comparing POR and CYP activity in V79-CYP3A94 and
V79-CYP3A94/DD-POR cells without or with Shield-1 incubation were analyzed
using one-way analysis of variance (ANOVA). The comparisons were made using
the Kruskal-Wallis Multiple-Comparison Z-Value Test (Dunn’s Test). Data were
analyzed with NCSS statistical software (version 2007, Kaysville, UT, USA). P
values ,0.05 were considered significant.
A flowchart of the experimental procedure is shown in Figure 1.
Results
Amplification, sequencing and cloning of the equine POR gene
Amplification and subsequent sequencing of the obtained equine POR genes
revealed one variation (c.569G .A) in liver samples of all four horses and another
variation in two out of four liver samples (c.112C .G) when compared with the
annotated equine POR gene at the EMBL data bank (NM_001122655 Both
variants resulted in one amino acid change, but none of them are located in
known functional domains of the POR. For further experiments, cDNA of one
horse with both variants was used. The complete CDS of the DD sequence and
equine POR was successfully cloned into the vector pRRL 2x RsrII TD. Colony
PCR confirmed the insertion of the equine POR with a band of approximately
2037 bp. Sequencing revealed no further mutations. The CDS of equine CYP3A94
was also successfully cloned and subsequent sequencing revealed no further
mutations.
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Production of two stable cell lines V79-CYP3A94 and V79-
CYP3A94/DD-POR
Native V79 cells were successfully and stably transduced with the corresponding
lentivirus vectors. Transduction efficiency of CYP3A94 and POR was tested by
immunocytochemistry using a specific antibody against the HA-tag and against
the DD protein, respectively. For both recombinant cell lines, single clones
showing a stable and strong fluorescence were selected for further experiments. To
prove the presence of CYP3A94 and POR in the recombinant V79 cells, gDNA
was extracted and analyzed. The complete CDS of both, CYP3A94 and POR, was
successfully amplified by PCR and sequencing revealed no further mutations.
POR protein expression
A specific antibody against the DD protein detected the DD/POR fusion protein
showing the expected band corresponding to a relative molecular mass of about
90 kDa. This is in agreement with the calculated molecular mass of the POR
(78 kDa) in addition to the DD protein (12 kDa). Actin was used as housekeeping
Figure 1. Flowchart of the experimental procedure. RNA was extracted from equine liver cells and equine POR and CYP3A94 were amplified and
sequenced. In order to regulate the enzyme POR, it was first cloned behind a destabilization domain (DD) into the vector pPTuner IRES2 to construct a DD/
POR fusion protein. Addition of the ligand Shield-1 results in binding to the DD domain prevents degradation; hence the DD/POR protein accumulates in the
cell. The DD/POR and CYP3A94 were cloned into the lentivirus vector pRRL and HEK T293 were transfected for virus production. To produce the stable
cells lines V79-CYP3A94 and V79-CYP3A94/DD-POR, V97 cells were transduced three times. POR and CYP3A94 were assessed for activity, localization,
ER-associated degradation (ERAD) and ubiquitin-proteasome system (UPS).
doi:10.1371/journal.pone.0113540.g001
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protein to assure the same amount of protein in each slot. Shield-1 is supposed to
protect the DD/POR protein from degradation and consequently, an increase in
DD/POR should be detected in samples with increasing Shield-1 concentrations.
However, the amount of POR protein decreased concentration-dependently as
depicted in Figure 2. At Shield-1 concentrations of 500 nM and 1 mM only about
half of the DD/POR protein remained.
POR activity
Cytochrome c reduction was significantly increased (p,0.05) in V79-CYP3A94/
DD-POR cells compared to V79-CYP3A94 cells as shown in Figure 3. Incubation
with increasing Shield-1 concentrations did not result in an increase of
cytochrome c reduction. No significant change in POR activity in V79-CYP3A94/
DD-POR cells was observed after incubation with Shield-1 compared to V79-
CYP3A94/DD-POR cells without Shield-1. To support these results, the cells were
incubated with 30 mM paraquat and cell viability was measured. POR is known to
catalyze the reduction of paraquat, which subsequently initiates the redox cycle
generating reactive oxygen species [33, 34]. No change in cell viability could be
detected after incubation with paraquat together with increasing Shield-1
concentrations (data not shown) confirming the results of the cytochrome c
reductase assay.
CYP3A94 activity
Equine CYP3A94 without POR metabolized BFC to the fluorescent product HFC
and thus was demonstrated to be active. Furthermore, CYP3A94 activity was
significantly increased in V79-CYP3A94/DD-POR cells compared to V79-
CYP3A94 cells without additional POR. CYP3A94 activity was shown to be more
than four-fold higher in V79-CYP3A94/DD-POR cells without incubation of
Shield-1. However, incubation with increasing Shield-1 concentrations resulted in
decreased CYP3A94 activity. After incubation with 1 mM Shield-1 for 24 hours,
the CYP3A94 activity was reduced by almost half (Figure 4).
Figure 5 shows the effect of tunicamycin, brefeldin-A, and MG132 on CYP3A94
activity in V79-CYP3A94/DD-POR cells. All three substances reduced the
CYP3A94 activity to approximately half of V79-CYP3A94/DD-POR activity
without Shield-1 incubation. The effect of the substances on cell viability is
illustrated in Figure 6.
Immunocytochemistry
Immunocytochemistry was performed to investigate the possibility of POR
transport from the ER to the Golgi apparatus. Simultaneous labeling of POR and
the ER or the Golgi apparatus in presence or absence of Shield-1 did not
demonstrate differences in co-localization of POR with both cell organelles
(Figure 7).
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Discussion
In this study, we demonstrated that heterologously expressed equine CYP3A94 is
metabolically active and co-expression of POR in V79 cells enhances its activity.
This finding indicates that the activity of CYP3A94 is dependent on an adequate
POR level. However, the regulation of POR levels through the fused DD motif
remained unsuccessful.
CYP3A94 metabolized BFC to the fluorescent product HFC as reported for
human CYP3A4 [29] and equine CYPs of the 3A subfamily. We have recently
demonstrated that metabolic reactions and effects of known CYP3A inhibitors
differed between the equine CYP3A isoforms investigated [25].
BFC is a suitable substance for screening the activity of CYPs because of its fast
and simple application and detection.
Western immunoblot analysis of V79-CYP3A94/DD-POR cell homogenates
revealed a protein with a molecular mass of about 90 kDa, thereby confirming
that POR fused to the DD motif was properly expressed. Accordingly, the POR
Figure 2. Incubation of V79-CYP3A94/DD-POR cells with Shield-1 leads to a decrease of POR protein.
(A) V79-CYP3A94/DD-POR cells (POR) were incubated with 100 nM, 500 nM, or 1 mM Shield-1 (Shld) for
24 hours. Total cell homogenates were used for Western immunoblot analysis with anti-DD antibody, anti-HA
antibody, and anti-actin antibody as a housekeeping protein. (B) Densitometric analysis of Western
immunoblot bands normalized to actin; all values are presented in percent AU per mg total cellular protein;
density of V79-CYP3A94/DD-POR cells without Shield-1 was set as 100%. Data are mean ¡ SD of 3
independent experiments.
doi:10.1371/journal.pone.0113540.g002
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activity in V79-CYP3A94/DD-POR cells was significantly higher compared to
V79-CYP3A94 cells. This result thus demonstrates that fusing the DD domain to
POR did not lead to gross folding defects, since the POR was metabolically active.
Apparently, the two DNA variants detected in the POR sequence expressed in our
experiment do not interrupt the function of POR. Importantly, a 4.5 fold higher
CYP3A94 activity was seen in V79-CYP3A94/DD-POR cells (without Shield-1)
when compared to V79-CYP3A94 cells, thus demonstrating that CYP3A94 activity
is dependent on an adequate POR level. These results also provide evidence that
co-expressed POR is able to transfer electrons to the CYP3A94 in our system.
Unexpectedly, the basal POR and CYP3A94 activity levels in V79-CYP3A94/
DD-POR cells without Shield-1 were higher than anticipated. The DD/POR
fusion protein was expected to be degraded with only marginal amount of POR
present in the cells [24, 35]. Our results indicate that the DD/POR protein is not
degraded as expected. As the UPS is located in the cytosol, degradation of the
fusion protein is dependent on its localization in the different cell compartments
[22]. In our case, POR is an enzyme attached N-terminally to the ER membrane
and degradation of DD/POR is dependent on the ER-associated degradation
system and the ER-unfolded protein response (UPR) [36, 37]. There is evidence
that degradation of DD is impaired if localized in the ER lumen [22], but no
previous studies on the fusion of DD with a membrane-bound enzyme in the ER
like the POR are available in the literature. The N-terminal end of POR serves as
Figure 3. POR activity is significantly increased in V79-CYP3A94/DD-POR cells. V79-CYP3A94/DD-
POR cells (POR) were incubated with 100 nM, 500 nM, or 1 mM Shield-1 for 24 hours. All values are
presented in percent reduced cytochrome c/min/mg total cellular protein; activity in V79-CYP3A94/DD-POR
cells without Shield-1 was set as 100%. Data are mean ¡ SD of 5 or more independent experiments;
significant differences to the control V79-CYP3A94 are marked by asterisks; * 5p,0.05.
doi:10.1371/journal.pone.0113540.g003
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an anchor to the membrane of the ER and its end appears to be flexible [38, 39].
Thus, it is possible that the DD protein reaches into the ER lumen and is not
recognized for degradation. The ERAD can be divided in four steps: substrate
recognition, dislocation across the lipid bilayer, addition of polyubiquitin adducts,
and degradation by the 26S proteasome. It is likely that the first or the second step
failed because the POR in our experiment is still functional and capable of
transferring electrons to the CYP. This would not be possible if the POR had
already been dislocated from the ER membrane by the ERAD (step 2) since the
POR is no longer able to transfer electrons to the CYPs if it is not attached to the
ER membrane [37, 39]. Alternatively, it is possible that the ER is less sensitive to
elevated DD levels and therefore the UPR is not activated, which would be
necessary for the ERAD to function efficiently [40].
To investigate some of these possibilities in our system, the effects of
tunicamycin, an ER stressor and the proteasome inhibitor MG132 were
investigated. Tunicamycin is known to activate the ER UPR. Indeed, incubation of
V79-CYP3A94/DD-POR cells with tunicamycin (1 mM, 6 hours) led to a
reduction of CYP3A94 activity indicating that the DD/POR protein is transported
into the cytosol and is degraded by the ubiquitin-proteasome system, thus
supporting the results of Sellmyer et al. [22]. Addition of the proteasome inhibitor
MG132 was expected to result in no change in CYP3A94 activity because DD/POR
without Shield-1 did not seem to be degraded as expected. The reduced CYP3A94
Figure 4. CYP3A94 activity is significantly increased in V79-CYP3A94/DD-POR cells, but decreases
after incubation with Shield-1. V79-CYP3A94/DD-POR cells (POR) were incubated with 100 nM, 500 nM,
or 1 mM Shield-1 for 24 hours. All values are presented in percent nmol HFC per mg total cellular protein;
activity in V79-CYP3A94/DD-POR cells without Shield-1 was set as 100%. Data are mean¡ SD of 6 or more
independent experiments; significant differences to V79-CYP3A94 cells are marked by asterisks; significant
differences to V79-CYP3A94/DD-POR without Shield-1 are marked by plus; significant differences to V79-
CYP3A94/DD-POR with 100 nM Shield-1 are marked by pound key; */ + /# 5p,0.05.
doi:10.1371/journal.pone.0113540.g004
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activity monitored after administration of the proteasome inhibitor can be
explained by reduced cell viability but nevertheless supports our data showing that
DD/POR is not degraded in the absence of Shield-1.
Further studies are needed to investigate the detailed degradation mechanism of
DD localized in the ER and possible impairment of processes such as ERAD or
UPR should be examined. Fusing the DD motif to the C-terminal part of the POR
protein located at the cytosolic side of the ER membrane could be tested in order
to avoid the DD protein reaching into the ER lumen. However, key functional
domains, like the NADPH binding site, are present C-terminally, thereby possibly
leading to the generation of non-functional POR proteins [41, 42].
A higher POR expression in presence of Shield-1 was expected. In contrast,
addition of Shield-1 to V79-CYP3A94/DD-POR cells showed no increase in POR
activity as measured by cytochrome c reduction. It is possible that the cytochrome
c reductase assay was not sensitive enough to register the changes in POR activity
Figure 5. Activity of V79-CYP3A94/DD-POR cells after incubation with tunicamycin, brefeldin A or
MG132. V79-CYP3A94/DD-POR cells (POR) were incubated with tunicamycin (Tc, 1 mM), brefeldin A (BFA,
3.57 mM) and MG132 (MG, 1 mM) for 6 hours, with and without simultaneous incubation with Shield-1 (1 mM,
6 hours) and BFC (100 nM, 6 hours). All values are presented in percent activity per mg total cellular protein;
activity in V79-CYP3A94/DD-POR cells without Shield-1 was set as 100%. Data are shown as mean¡ SD of
six independent experiments; significant differences to the control V79-CYP3A94 are marked by asterisks;
significant differences to V79-CYP3A94/DD-POR without Shield-1 are marked by plus; * / +5p,0.05.
doi:10.1371/journal.pone.0113540.g005
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after incubation with Shield-1. Thus, we used paraquat as an alternative method
to monitor POR levels. POR is known to catalyze the reduction of paraquat that
initiates the redox cycle resulting in the generation of reactive oxygen species
[33, 34]. If Shield-1 would increase the amount of POR, a decrease in cell viability
would result. Paraquat did not change cell viability supporting the results of the
cytochrome c reductase assay.
Intriguingly, CYP3A94 activity even decreased significantly after incubation of
V79-CYP3A94/DD-POR cells with Shield-1. Only half of the basal activity could
be measured after incubation with 500 nM and 1 mM Shield-1. Shield-1 is
supposed to have a high affinity to DD and therefore, unspecific binding to POR
or another structure is extremely unlikely [43–45]. Alternatively, proper binding
of Shield-1 to DD may generate long-range effects and hence disturb the
conformational changes in POR that are required to allow electron transfer to the
CYP. Thus, inhibition or modulation of these conformational changes will have a
Figure 6. Viability of V79-CYP3A94/DD-POR cells after incubation with tunicamycin, brefeldin A or
MG132. V79-CYP3A94/DD-POR cells (POR) were incubated with tunicamycin (Tc, 1 mM), brefeldin A (BFA,
3.57 mM) and MG132 (MG, 1 mM) for 6 hours, with and without simultaneous incubation with Shield-1 (1 mM,
6 hours). All values are presented in percent AFU per mg total cellular protein; viability of V79-CYP3A94/DD-
POR cells without Shield-1 was set as 100%. Data are mean¡ SD of 6 independent experiments; significant
differences to the control V79-CYP3A94 are marked by asterisks; significant differences to V79-CYP3A94/
DD-POR with 1 mM Shield-1 are marked by plus; +/ *5p,0.05.
doi:10.1371/journal.pone.0113540.g006
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Figure 7. Immunofluorescence staining of DD-POR, Golgi apparatus, and ER. V79-CYP3A94/DD-POR
cells (POR) and V79-CYP3A94 were incubated with or without Shield-1 (1 mM), 1 mM) for 6 hours. The anti-
DD antibody (red) was used as marker for POR, calnexin and gigantin were used as specific marker for ER
(A) and Golgi apparatus (B) (green), respectively. Nuclei were stained with Hoechst 33342 (bottom row).
Scale bar 10 mm for all images.
doi:10.1371/journal.pone.0113540.g007
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direct impact on CYP3A94 activity [39, 41, 46]. It has been reported that the N-
terminal end of POR is flexible and susceptible to proteolytic cleavage. Thus, it is
tempting to speculate that the C-terminal end is released from the membrane
anchor due to conformational changes after Shield-1 binding. Cytochrome c is
not a natural electron acceptor, in contrast to CYP molecules, and it does not need
membrane-bound POR. In fact, it was reported that cytochrome c reduction can
be increased even if POR is present in soluble form [39, 46]. If that would be the
case, POR may remain functional for the cytochrome c, while being defective for
CYPs [39] thus explaining the decreased CYP3A94 yet constant POR activity.
The quantitative protein analysis of POR showed a concentration-dependent
decrease of POR after Shield-1 incubation, supporting the findings of decreased
CYP3A94 activity through Shield-1. Possible explanations include a diminished binding
of the antibody to the DD/POR protein after Shield-1 incubation due to structural
changes, or degradation of the DD/POR protein due to the misfolded protein. For
further investigation, molecular modeling of POR in the presence or absence of Shield-1
might help to understand the effect of Shield-1 on the POR structure.
It has been reported that Shield-1 might induce the transport of the protein out
of the ER to the Golgi apparatus [22]. Incubation of brefeldin A, an inhibitor of
the transport from ER to the Golgi apparatus resulted in a decrease in CYP3A94
activity. It is likely that this is due to the reduced viability after incubation with
3.57 mM brefeldin A for 6 hours. If the transport would be inhibited, an increase
in POR and hence an increase in CYP3A94 would be expected. The results from
our immunocytochemical experiments support these results since no differences
were obtained in presence or absence of Shield-1. Therefore, a transport of POR
from the ER to the Golgi apparatus seems unlikely.
Conclusions
We could demonstrate that equine CYP3A94 is metabolically active and its
activity is dependent on an adequate level of POR.
POR could not be regulated with the pPTuner system. On the one hand, the
DD/POR protein without Shield-1 was not degraded as intended and on the other
hand, incubation of Shield-1 led to a decrease of POR protein and CYP3A94
activity.
Although the regulation of POR was not successful, the cell line V79-CYP3A94/
DD-POR can be used for further experiments to characterize the equine CYP3A94
since the CYP activity was significantly enhanced with co-expressed POR.
To further investigate the optimal CYP:POR ratio, other tunable systems like
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